Table 1.
Baseline characteristics of HAART-treated HIV-infected adults with suboptimal immune response within the IDI research cohort
| Variables | Active drug first (N = 15) |
Placebo first (N = 15) |
|---|---|---|
| Demographic data | ||
| Female n (%) | 7 (46.7) | 10 (66.7) |
| Median age (IQR) | 41 (40–50) | 47 (43–51) |
| Marital status n (%) | ||
| Married/cohabiting | 10 (66.7) | 6 (40.0) |
| Divorced | 3 (20.0) | 4 (26.7) |
| Widowed | 2 (13.3) | 5 (33.3) |
| Occupation n (%) | ||
| Unemployed | 4 (26.7) | 2 (13.3) |
| Employed | 11 (73.3) | 13 (86.7) |
| Education n (%) | ||
| Primary | 6 (40.0) | 6 (40.0) |
| Secondary and above | 9 (60.0) | 9 (60.0) |
| CD4 at HAART initiation, median (IQR) | 78 (43–162) | 92 (50–130) |
| First-line HAART regimen, n (%) | ||
| ZDV+3TC+NVP | 5 (33.3) | 7 (46.7) |
| ZDV+3TC+EFZ | 5 (33.3) | 3 (20.0) |
| TDF+FTC+EFZ | 1 (6.7) | 0 (0.0) |
| TDF+FTC+NVP | 1 (6.7) | 0 (0.0) |
| Others | 2 (13.3) | 3 (20.0) |
| Concurrent medication* | ||
| Antihypertensive n (%) | 0 (0.0) | 3 (20) |
| Cotrimoxazole prophylaxis | 15 (100) | 14 (87) |
| Fluconazole | 0 (0) | 1 (7) |
| Physical examination | ||
| Axillary temperature, median (IQR) | 36.0 (35.7–36.4) | 36.1 (35.8–36.4) |
| BMI, median (IQR) | 20.8 (19.5–21.6) | 24.0 (21.1–26.4) |
| Waist circumference, median (IQR) | 79.0 (72.0–80.0) | 88.0 (77.0–96.0) |
| Hip circumference, median (IQR) | 88.0 (86.0–95.0) | 97.0 (93.0–104.0) |
| Median waist to hip ratio(IQR) | 0.9 (0.8–0.9) | 0.9 (0.9–1.0) |
| Median pulse rate (IQR) | 80.0 (70.0–92.0) | 84.0 (77.0–94.0) |
| Systolic blood pressure, median (IQR) | 110 (100–149) | 140 (112– 163) |
| Diastolic blood pressure, median (IQR) | 74 (65–82) | 89 (70–100) |
| HB (g/dl), median (IQR) | 14 (12.9–15.2) | 13.1 (12.2–14.2) |
| WBC (103 cells/Ul), median (IQR) | 3.6 (2.8–3.8) | 3.45 (3.0–4.1) |
| ESR (mm/h), median (IQR) | 11 (3–15) | 11 (3–15) |
*
No participants had any history of medication with non-steroidal anti-inflammatory drugs (NSAIDS), steroids, use of statins, family history of stroke and sudden death, febrile illness or confirmed malaria within 2 weeks preceding the study.
WBC, White blood cell count, normal adult range, 4.0–11.0 × 103 cells/Ul; HB, haemoglobin, normal range, 12–18 g/dl; ESR, erythrocyte sedimentation rate, normal range (male, female, elderly, up to 10, 15, 20 mm/h).